Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFF: Lebrikizumab in Idiopathic Pulmonary Fibrosis
NCT01872689Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2013
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of lebrikizumab in idiopathic pulmonary fibrosis (IPF) (4 cohorts), sponsored by Roche. Primary endpoint: Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity at 52 weeks. Started Oct 2013; status: completed.
02
Drugs
lebrikizumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01872689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01872689.